Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G PROCAINE versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G PROCAINE versus VEETIDS 500.
PENICILLIN G PROCAINE vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
1.2 million to 2.4 million units intramuscularly once daily for most infections (e.g., uncomplicated pneumonia); for neurosyphilis, 2.4 million units intramuscularly once daily plus probenecid 500 mg orally four times daily for 10-14 days. Administer deep IM injection, not IV.
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5-1 hour in patients with normal renal function. Clinically, the prolonged absorption from the intramuscular depot results in sustained serum concentrations, with effective levels lasting 12-24 hours.
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Primarily renal excretion via tubular secretion and glomerular filtration. Approximately 60-90% of a dose is excreted unchanged in urine within 24 hours. Biliary/fecal elimination is minor (<10%).
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic